Contineum Therapeutics Reports Phase 2 MOONLIGHT-1 Trial Results

What Happened
Contineum Therapeutics, Inc. (CTNM) filed a Form 8-K on September 14, 2026 announcing that it issued a press release reporting the results of the MOONLIGHT-1 Phase 2 clinical trial. The trial evaluated the efficacy, safety, and tolerability of JNJ-5120/PIPE-307 as a monotherapy in adult participants with major depressive disorder. Johnson & Johnson is developing JNJ-5120/PIPE-307 under a global license and development agreement with Contineum. The press release is furnished as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: September 14, 2026 (Form 8-K, Item 8.01 - Other Events).
• Trial: MOONLIGHT-1, Phase 2, monotherapy in adult major depressive disorder.
• Drug: JNJ-5120/PIPE-307 — development is being handled by Johnson & Johnson under a global license/development agreement with Contineum.
• Press release with results is attached as Exhibit 99.1 to the 8-K; the report was signed by CFO Peter Slover.

Why It Matters
Contineum publicly disclosed Phase 2 trial results and formally filed them with the SEC, making the data available to investors and analysts. The involvement of Johnson & Johnson under a global license and development agreement is a material partnership detail noted in the filing. Investors should review the furnished press release (Exhibit 99.1) for the full efficacy and safety data and monitor the company for any follow-up disclosures or regulatory and development updates.